We are delighted to announce that WuXi’s genomics clinical laboratory inShanghai has successfully passed the survey by theCenters for Medicare and Medicaid Services of theU.S. Department of Health and Human Services relating to CLIA (Clinical Laboratory Improvement Amendments) standards, thereby receiving CLIA certification. WuXi’s laboratory is now the only CLIA-certified clinical laboratory inChina.

CLIA standards, established by the U.S. Congress in 1988, relate to all clinical laboratory testing on specimens derived from humans in the United States to give information for the assessment, diagnosis, prevention, and treatment of disease or other impairment of health. The objective of CLIA is to ensure the accuracy, reliability and timeliness of test results regardless of where the test is performed. Receipt of a CLIA certificate allows WuXi’s genomics laboratory to undertake certain clinical trial gene sequencing projects.

Our CLIA certification is an important milestone in realizing our vision to build an open-access technology and capability platform that enables anyone and any company to discover and develop therapeutic products to benefit patients.

Related Links:

What Does the CLIA Certification Mean to WuXi and Its Clients?

“Genome Center Poised for Growth” – Genomeweb Interview